[1]于吉峰.调节性T细胞在移植物抗宿主病免疫治疗中的研究进展[J].郑州大学学报(医学版),2019,(05):685-688.[doi:10.13705/j.issn.1671-6825.2019.01.036]
点击复制

调节性T细胞在移植物抗宿主病免疫治疗中的研究进展()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2019年05期
页码:
685-688
栏目:
综述
出版日期:
2019-09-20

文章信息/Info

作者:
于吉峰
郑州大学第一附属医院血液科 郑州 450052
关键词:
调节性T细胞 移植物抗宿主病 细胞免疫治疗
DOI:
10.13705/j.issn.1671-6825.2019.01.036

参考文献/References:

[1] HORI S,NOMURA T,SAKAGUCHI S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science,2003,299(5609):1057
[2] SAKAGUCHI S,SAKAGUCHI N,ASANO M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol,1995,155(3):1151
[3] SAKAGUCHI S,ONO M,SETOGUCHI R,et al.Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease[J].Immunol Rev,2006,212:8
[4] BERES AJ,DROBYSKI WR.The role of regulatory T cells in the biology of graft versus host disease[J]. Front Immunol,2013,4:163
[5] HEINRICHS J, BASTIAN D, VEERAPATHRAN A, et al. Regulatory T-cell therapy for graft-versus-host disease[J]. J Immunol Res Ther,2016,1(1):1
[6] WOLF D, BARRERAS H, BADER CS, et al. Marked in vivo donor regulatory T cell expansion via interleukin-2 and TL1A-Ig stimulation ameliorates graft-versus-host disease but preserves graft-versus-leukemia in recipients after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant,2017, 23(5):757
[7] HOTTA M,YOSHIMURA H,SATAKE A,et al.GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells[J].Eur J Immunol,2019,49(1):179
[8] TRZONKOWSKI P,BIENIASZEWSKA M,JUSCINSKA J,et al.First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells[J].Clin Immunol,2009,133(1):22
[9] BRUNSTEIN CG,MILLER JS,CAO Q,et al.Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics[J].Blood,2011,117(3):1061
[10]BETTS BC,PIDALA J,KIM J,et al.IL-2 promotes early Tregs reconstitution after allogeneic hematopoietic cell transplantation[J].Haematologica,2017,102(5):948
[11]THEIL A,TUVE S,OELSCHLÄGEL U,et al.Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease[J].Cytotherapy,2015,17(4):473
[12]KENNEDY-NASSER AA,KU S,CASTILLO-CARO P,et al.Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity[J].Clin Cancer Res,2014,20(8):2215
[13]KORETH J, KIM HT, JONES KT, et al. Efficacy, durability, and reponse predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease[J]. Blood,2016, 128(1):130
[14]COPSEL SN, LIGHTBOURN CO, BARRERAS H, et al. BET bromodomain inhibitors which permit Tregs function enable a combinatorial strategy to suppress GVHD in pre-clinical allogeneic HSCT[J]. Front Immunol,2019,9:3104
[15]WOLF D,BADER CS,BARRERAS H,et al.Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models[J].JCI Insight,2018,3(20):121717
[16]KELLNER JN,DELEMARRE EM,YVON E,et al.Third party,umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation:feasibility,safety and immune reconstitution[J].Oncotarget,2018,9(86):35611
[17]JEON YW,LIM JY,IM KI,et al.Enhancement of graft-versus-host disease control efficacy by adoptive transfer of type 1 regulatory T cells in bone marrow transplant model[J].Stem Cells Dev,2019,28(2):129
[18]DEL PAPA B,RUGGERI L,URBANI E,et al.Clinical-grade-expanded regulatory T cells prevent graft-versus-host disease while allowing a powerful T cell-dependent graft-versus-leukemia effect in murine models[J].Biol Blood Marrow Transplant,2017,23(11):1847
[19]STAMOU P,MARIOLI D,PATMANIDI AL,et al.Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease[J].Cytotherapy,2017,19(4):521
[20]ROMANO M,TUNG SL,SMYTH LA,et al.Tregs therapy in transplantation:a general overview[J].Transpl Int,2017,30(8):745
[21]BRUNSTEIN CG,MILLER JS,MCKENNA DH,et al.Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect[J].Blood,2016,127(8):1044
[22]DIJKE IE,HOEPPLI RE,ELLIS T,et al.Discarded human thymus is a novel source of stable and long-lived therapeutic regulatory T cells[J].Am J Transplant,2016,16(1):58
[23]GU J,NI XH,PAN XX,et al.Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions[J].Cell Mol Immunol,2017,14(6):521
[24]FUHRMAN CA,YEH WI,SEAY HR,et al.Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226[J].J Immunol,2015,195(1):145

相似文献/References:

[1]杨 兵),林爱琴),罗晓华),等.不同严重程度冠心病患者外周血Treg和Th17细胞的测定[J].郑州大学学报(医学版),2018,(05):658.[doi:10.13705/j.issn.1671-6825.2018.04.007]
 YANG Bing),LIN Aiqin),LUO Xiaohua),et al.Detection of Treg and Th17 cells in peripheral blood of patients with different severity of coronary heart disease[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(05):658.[doi:10.13705/j.issn.1671-6825.2018.04.007]

备注/Memo

备注/Memo:
【基金项目】郑州大学第一附属医院特殊人才项目基金
【作者简介】于吉峰,通信作者,男,1963年2月生,硕士,教授,研究方向:血液病免疫,E-mail:yujifengzzu@163.com
更新日期/Last Update: 2019-09-20